Background/Aims: Limited data are available about spontaneous growth, pubertal growth spurt and the long-term outcome of patients suffering from familial male precocious puberty (FMPP). We report on a boy with FMPP whose growth pattern and pubertal development was studied longitudinally without treatment. Methods: Long-term prospective follow-up without treatment of a 6.2-year-old boy with FMPP having inherited a mutation of the LH receptor gene (A568V) from his father. Results: The pubertal growth spurt was of unusual maximal amplitude (growth rate 12.4 cm/year at the age of 5–6 years) and of extraordinary duration lasting for 5.2 years from age 3.8 to 9.0 years. No deterioration of height potential was observed. Height (174 cm) was within target height range (171.5–188.5 cm) at age 13 years. No central precocious puberty occurred. Conclusion: FMPP is an experiment of nature demonstrating that the amplitude and duration of the pubertal growth spurt are much more variable than previously described. Furthermore, this case emphasizes that the indication for treatment is highly dependent on intrafamilial and individual factors.

Schedewie HK, Reiter EO, Beitins IZ, Seyed S, Wooten VD, Jimenez JF, Aiman EJ, DeVane GW, Redman JF, Elders MJ: Testicular Leydig cell hyperplasia as a cause of familial sexual precocity. J Clin Endocrinol Metabol 1981;52:271–278.
Rosenthal SM, Grumbach MM, Kaplan SL: Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): Effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metabol 1983;57:571–579.
Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993;365:652–654.
Holland FJ, Kirsch SE, Selby R: Gonadotropin-independent precocious puberty (‘testotoxicosis’): Influence of maturational status on response to ketoconazole. J Clin Endocrinol Metabol 1987;64:328–333.
Laue L, Jones J, Barnes KM, Cutler GB Jr: Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metabol 1993;76:151–155.
Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr: Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989;320:496–502.
Bertelloni S, Baroncelli GI, Lala R, Cappa M, Matarazzo P, De Sanctis C, Saggese G: Long-term outcome of male-limited gonadotropin-independent precocious puberty. Horm Res 1997;48:235–239.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: Revised use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.
Gromoll J, Partsch CJ, Simoni M, Nordhoff V, Sippell WG, Nieschlag E, Saxena BB: A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty. J Clin Endocrinol Metabol 1998;83:476–480.
Latronico AC, Anasti J, Arnhold IJ, Mendonca BB, Domenice S, Albano MC, Zachman K, Wajchenberg BL, Tsigos C: A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metabol 1995;80:2490–2494.
Latronico AC, Abell AN, Arnhold IJ, Liu X, Lins TS, Brito VN, Billerbeck AE, Segaloff DL, Mendonca BB: A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metabol 1998;83:2435–2440.
Latronico AC, Lins TS, Brito VN, Arnhold IJ, Mendonca BB: The effect of distinct activating mutations of the luteinizing hormone receptor gene on the pituitary-gonadal axis in both sexes. Clin Endocrinol 2000;53:609–613.
Egli CA, Rosenthal SM, Grumbach MM, Montalvo JM, Gondos B: Pituitary gonadotropin-independent male-limited autosomal dominant sexual precocity in nine generations: Familial testotoxicosis. J Pediatr 1985;106:33–40.
Karlberg J, Fryer JG, Engstrom I, Karlberg P: Analysis of linear growth using a mathematical model. II. From 3 to 21 years of age. Acta Paediatr Scand 1987(suppl 337):12–29.
Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989(suppl 52):1–125.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child 1966;41:454–471.
Rosenfield RL: Selection of children with precocious puberty for treatment with gonadotropin-releasing hormone analogs. J Pediatr 1994;124:989–991.
Oerter-Klein K: Precocious puberty: Who has it? Who should be treated? J Clin Endocrinol Metabol 1999;84:411–414.
Léger J, Reynaud R, Czernichow P: Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000;137:819–825.
Partsch CJ, Heger S, Sippell WG: Management and outcome of central precocious puberty. Clin Endocrinol 2002;56:129–148.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.